FR in Stored Plasma
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The folate receptor (FR) is a cell over expressed on the surface of certain cancers, this occurs most frequently in ovarian cancers. Some normal tissues also express the FR, however in these normal tissues, the FR is usually located on the tissue surface that is inaccessible to circulating drugs. As such, drugs which target the FR may potentially be used to target cancers which overexpress the FR while reducing toxicity to normal tissues. Therefore the ability to measure FR levels from different cancer types may help to select patients who are most likely to benefit from treatment with FR targeted therapies. Once such drug BGC945 is currently being tested in preclinical study at the Institute of Cancer Research
| Condition |
|---|
|
Ovarian Cancer |
| Study Type: | Observational |
| Official Title: | Measurement of the Folate Receptor in Stored Plasma From Patients With Ovarian Cancer |
- To measure the levels of soluble folate receptor in stored plasma obtained from patients with ovarian cancer [ Designated as safety issue: No ]
| Estimated Enrollment: | 27 |
| Study Start Date: | July 2008 |
| Estimated Study Completion Date: | February 2011 |
| Estimated Primary Completion Date: | February 2011 (Final data collection date for primary outcome measure) |
FR may be released from the cancer cells in the blood. We have developed a method in the laboratory which has been able to measure the FR obtained from cancer cells in culture which has been added into blood. We would like to study if this method is able to measure the FR in stored plasma samples obtained from patients with ovarian cancer, so that it may be developed as a method for selecting patients for FR-target treatments such as BGC 945.
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
In the first stage of the study 13 samples will be analysed. If thee is one or more positive results the study will progress to the 2nd state to include 14 more samples.
Inclusion Criteria:
- Patients with ovarian cancer who have given informed consent to have blood collected for the plasma bank in the 'Pharmacogenetics and proteomics studies in patients receiving novel anticaner agents' study.
Exclusion Criteria:
- Patients who have withdrawn consent form their blood stored within the 'Pharmacogenetics and proteomics studies in patients receiving novel anticancer agents' study to be used for research.
Contacts and Locations| Contact: Stan Kaye | 02086613539 | stan.kaye@rmh.nhs.uk |
| Contact: Matthew Ng | 02087224283 | matthew.ng@icr.ac.uk |
| United Kingdom | |
| Royal Marsden NHS Foundation Trust | Recruiting |
| Sutton, Surrey, United Kingdom, SM2 5PT | |
| Contact: Stan Kaye 02086613541 stan.kaye@rmh.nhs.uk | |
| Contact: Matthew Ng 02087224283 matthew.ng@rmh.nhs.uk | |
| Principal Investigator: Stan Kaye | |
More Information
No publications provided
| Responsible Party: | Prof Stan Kaye, Institute of Cancer Research |
| ClinicalTrials.gov Identifier: | NCT00787514 History of Changes |
| Other Study ID Numbers: | CCR3029 |
| Study First Received: | November 6, 2008 |
| Last Updated: | November 6, 2008 |
| Health Authority: | United Kingdom: National Health Service |
Keywords provided by Royal Marsden NHS Foundation Trust:
|
ovarian cancer, folate receptor, plasma |
Additional relevant MeSH terms:
|
Ovarian Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases |
Genital Diseases, Female Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases Gonadal Disorders |
ClinicalTrials.gov processed this record on May 23, 2013